---
title: "Dataset 48: Precision Medicine - Predicting Therapeutic Response in Cancer Treatment"
format: html
---

# Overview

This dataset contains clinical and molecular data from cancer patients to predict their response to a novel targeted therapy. The dataset combines genetic profiling, clinical assessments, and biomarker measurements to enable the development of precision medicine models that can identify which patients are most likely to benefit from treatment.

::: {.callout-note icon=false}
## Download Dataset

<div style="display: flex; gap: 10px; margin-top: 10px;">
  <a href="../csv/ds048_biology_treatment_response_respondernon_responder.csv" download class="btn btn-primary" style="text-decoration: none; padding: 10px 20px; background-color: #0d6efd; color: white; border-radius: 5px; font-weight: bold;">
    ðŸ“¥ Download Clean Version
  </a>
  <a href="../csv/ds048_biology_treatment_response_respondernon_responder_dirty.csv" download class="btn btn-secondary" style="text-decoration: none; padding: 10px 20px; background-color: #6c757d; color: white; border-radius: 5px; font-weight: bold;">
    ðŸ“¥ Download Dirty Version
  </a>
</div>

**Clean Version**: Complete data with no missing values or outliers
**Dirty Version**: Contains missing values and outliers for data cleaning practice
:::


# Background and Use Case

In the era of precision medicine, oncologists face the critical challenge of selecting the most effective treatment for each individual cancer patient. Traditional "one-size-fits-all" approaches often result in suboptimal outcomes, with many patients experiencing severe side effects from treatments that ultimately prove ineffective for their specific cancer profile.

A major cancer research center has been conducting clinical trials for a promising new targeted therapy designed to treat advanced solid tumors. While the treatment shows remarkable efficacy in some patients, achieving complete or partial remission, approximately 40% of patients show little to no response while still experiencing significant side effects and treatment costs. The research team has collected comprehensive molecular and clinical data from 500,000 patients who completed the treatment protocol.

The hospital's precision medicine initiative aims to develop a predictive model that can identify patients most likely to respond to this therapy before treatment begins. This would allow clinicians to make more informed treatment decisions, potentially sparing non-responders from unnecessary side effects while ensuring responders receive optimal care. Such a model could revolutionize patient care by enabling truly personalized treatment selection.

# Problem Statement

Given a patient's genetic profile, disease characteristics, demographics, and biomarker levels, predict whether they will respond positively to the targeted therapy (binary classification: Responder vs. Non-responder).

# Target Variable

**Treatment Response (Responder/Non-responder)**: This binary variable indicates whether a patient achieved a clinically meaningful response to the targeted therapy, defined as either partial response (â‰¥30% tumor shrinkage) or complete response (disappearance of all target lesions) according to RECIST criteria, sustained for at least 3 months. Responders represent patients who derived significant clinical benefit from the treatment, while non-responders showed stable disease, progressive disease, or could not tolerate the therapy. Accurately predicting this outcome is crucial for optimizing patient care, reducing unnecessary toxicity, and improving resource allocation in cancer treatment.

# Predictor Variables

- **Genetic Profile**: Comprehensive genomic analysis including mutation status of key oncogenes and tumor suppressor genes (e.g., TP53, KRAS, EGFR, PIK3CA), microsatellite instability status, tumor mutational burden, and relevant gene expression signatures. This molecular fingerprint is critical as targeted therapies often work by exploiting specific genetic vulnerabilities in cancer cells.

- **Disease Severity**: Clinical staging information including tumor size, extent of metastasis (TNM staging), performance status (ECOG score), and disease progression rate. More advanced disease may respond differently to treatment and affects prognosis significantly.

- **Age**: Patient age at treatment initiation, which influences drug metabolism, treatment tolerance, immune system function, and overall treatment response. Younger patients often have better treatment outcomes but may also have more aggressive disease subtypes.

- **Comorbidities**: Presence and severity of concurrent medical conditions such as cardiovascular disease, diabetes, kidney dysfunction, or autoimmune disorders. Comorbidities can affect drug metabolism, increase toxicity risk, and influence overall treatment response and patient outcomes.

- **Biomarkers**: Circulating and tissue-based biomarkers including inflammatory markers (CRP, cytokines), metabolic indicators, circulating tumor DNA levels, immune system markers (lymphocyte counts, PD-L1 expression), and drug-specific biomarkers that may predict treatment efficacy.

# Dataset Versions

This dataset is provided in two versions:

- **Clean Version** (`ds048_biology_treatment_response_respondernon_responder.csv`): Ideal for initial model development and learning, with complete data for all patients and standardized measurements
- **Dirty Version** (`ds048_biology_treatment_response_respondernon_responder_dirty.csv`): Contains 2% missing values and 1% outliers, simulating real-world data quality issues such as incomplete lab results, measurement errors, and missing genetic test results

# Suggested Approaches

- **Random Forest**: Excellent for handling mixed data types and capturing complex interactions between genetic and clinical variables while providing feature importance rankings
- **Gradient Boosting (XGBoost/LightGBM)**: Powerful ensemble method that often performs well on clinical prediction tasks with structured data
- **Logistic Regression with Regularization**: Provides interpretable coefficients crucial for clinical decision-making and regulatory approval of predictive models

# Dataset Details

| Property | Value |
|----------|-------|
| Dataset ID | 48 |
| Domain | Biology |
| Problem Type | Classification |
| Number of Rows | 500,000 |
| Clean Version | `csv/ds048_biology_treatment_response_respondernon_responder.csv` |
| Dirty Version | `csv/ds048_biology_treatment_response_respondernon_responder_dirty.csv` |
| Missing Values (Dirty) | 2% |
| Outliers (Dirty) | 1% |

# Notes

This is a synthetic dataset generated for educational purposes. The relationships between variables have been designed to be realistic and pedagogically useful while maintaining interpretability. The dataset reflects real-world challenges in precision medicine, including class imbalance, complex feature interactions, and the integration of multi-modal clinical and molecular data.